466 related articles for article (PubMed ID: 33658996)
1. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
2. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
Gong X; Chen X; Kuligowski ME; Liu X; Liu X; Cimino E; McGee R; Yeleswaram S
Am J Clin Dermatol; 2021 Jul; 22(4):555-566. PubMed ID: 33982267
[TBL] [Abstract][Full Text] [Related]
4. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
Simpson EL; Bissonnette R; Chiesa Fuxench ZC; Kallender H; Sturm D; Ren H; Stein Gold LF
J Dermatolog Treat; 2024 Dec; 35(1):2310633. PubMed ID: 38297490
[No Abstract] [Full Text] [Related]
6. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
Blauvelt A; Kircik L; Papp KA; Simpson EL; Silverberg JI; Kim BS; Kwatra SG; Kuligowski ME; Venturanza ME; Wei S; Szepietowski JC
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):137-146. PubMed ID: 36066323
[TBL] [Abstract][Full Text] [Related]
7. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
Krajewski PK; Szepietowski JC
Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
[TBL] [Abstract][Full Text] [Related]
11. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
13. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
[TBL] [Abstract][Full Text] [Related]
14. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
[TBL] [Abstract][Full Text] [Related]
15. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
16. Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice.
Noguchi A; Tominaga M; Takahashi N; Matsuda H; Kamata Y; Umehara Y; Ko KC; Suga Y; Ogawa H; Takamori K
J Dermatol Sci; 2017 Apr; 86(1):54-62. PubMed ID: 28069324
[TBL] [Abstract][Full Text] [Related]
17. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
[TBL] [Abstract][Full Text] [Related]
18. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
19. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]